Goy Lends Insight on Acalabrutinib and Ibrutinib in MCL

In an interview with OncLive, Andre’ Goy, M.D., chair and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, Hackensack University Medical Center, discussed the excitement surrounding acalabrutinib, as well as emerging ibrutinib combination strategies.

Read full article on